Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

9908  relevant articles (1231 outcomes, 1253 trials/studies) found for this Disease

Acute Myelogenous Leukemia; Acute Myeloblastic Leukemia; Myelogenous Leukemia, Acute; Acute Myelocytic Leukemia; Acute Nonlymphocytic Leukemia; Leukemia, Myeloid, Acute; ANLL; Acute Myeloid Leukemia with Maturation; Acute Myeloid Leukemia without Maturation; Leukemia, Myeloblastic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Acute, M1; Leukemia, Myeloid, Acute, M2; Leukemia, Nonlymphoblastic, Acute; Myeloblastic Leukemia, Acute; Myelocytic Leukemia, Acute; Myeloid Leukemia, Acute, M1; Myeloid Leukemia, Acute, M2; Nonlymphoblastic Leukemia, Acute; Acute Myeloblastic Leukemias; Acute Myelocytic Leukemias; Acute Myelogenous Leukemias; Acute Myeloid Leukemias; Acute Nonlymphoblastic Leukemia; Acute Nonlymphoblastic Leukemias; Acute Nonlymphocytic Leukemias; Leukemia, Acute Myeloblastic; Leukemia, Acute Myelocytic; Leukemia, Acute Myelogenous; Leukemia, Acute Myeloid; Leukemia, Acute Nonlymphoblastic; Leukemia, Acute Nonlymphocytic; Leukemias, Acute Myeloblastic; Leukemias, Acute Myelocytic; Leukemias, Acute Myelogenous; Leukemias, Acute Myeloid; Leukemias, Acute Nonlymphoblastic; Leukemias, Acute Nonlymphocytic; Myeloblastic Leukemias, Acute; Myelocytic Leukemias, Acute; Myelogenous Leukemias, Acute; Myeloid Leukemias, Acute; Nonlymphoblastic Leukemias, Acute; Nonlymphocytic Leukemias, Acute; Leukemia, Myelogenous, Acute; Leukemia, Nonlymphocytic, Acute; Myeloid Leukemia, Acute; Nonlymphocytic Leukemia, Acute

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Leukemia
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome)
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

Experts

1.	Marcucci, Guido: 28 articles (11/2008 - 09/2003)
2.	Kantarjian, Hagop: 26 articles (03/2008 - 01/2002)
3.	Cortes, Jorge: 25 articles (09/2008 - 08/2002)
4.	Estey, Elihu: 25 articles (11/2007 - 01/2002)
5.	Faderl, Stefan: 23 articles (10/2008 - 08/2002)
6.	Bloomfield, Clara D: 22 articles (11/2008 - 08/2002)
7.	Kantarjian, Hagop M: 20 articles (10/2008 - 06/2002)
8.	Giles, Francis J: 20 articles (01/2007 - 06/2002)
9.	Giles, Francis: 18 articles (10/2007 - 01/2002)
10.	Hiddemann, Wolfgang: 18 articles (04/2007 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Acute Myeloid Leukemia:

1.	Cytarabine (Cytosar-U)FDA LinkGeneric 11/01/2009 - "The most effective regimen for patients with acute myeloid leukemia (AML) who do not achieve complete remission (CR) after one course of cytarabine and an anthracycline has not been extensively studied. " 01/01/1990 - "In addition, exposure of leukemic myeloblasts to Ara-C and dCyd for 96 h in culture medium lacking PHA-LCM eliminated the secondary plating efficiency (PE2) of leukemic colonies in 11 of 13 samples assayed and reduced values dramatically in the remaining 2. Substantial preservation of CFU-GM formation was also noted when normal bone marrow samples depleted of T cells and marrows obtained from two patients with ANLL in remission were assayed. " 11/05/2009 - "An international, randomized (2:1), double-blind, placebo-controlled study was conducted to compare complete remission (CR) rates and overall survival (OS) in patients with first relapse acute myeloid leukemia (AML) treated with laromustine and high-dose cytarabine (HDAC) versus HDAC/placebo. " 08/01/2000 - "The Eastern Cooperative Oncology Group (ECOG) conducted a prospective phase III study in patients with relapsed/refractory acute myeloid leukemia (AML) to evaluate whether administration of repeated courses of low-dose cytarabine (LDAC) maintenance therapy after induction of complete remission in advanced AML would improve disease-free and overall survival. " 09/01/2005 - "A reference group was built up by collecting 40 acute myeloid leukemia patients who received high-dose cytosine arabinoside as late intensification and whose complete remission lasted more than 10 months. " Order ALL the reference details at left...
2.	Daunorubicin (Cerubidine)FDA LinkGeneric 05/01/2000 - "De novo ANLL at diagnosis that achieved complete remission (CR) were significantly more sensitive to daunorubicin compared to those who didn't achieve CR (P<0.05). " 07/01/2003 - "Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia." 02/01/2000 - "The objective of the present study was to characterize the heterogeneity in the accumulation and efflux of daunorubicin in various subpopulations of mononuclear cells isolated from patients with acute myeloid leukemia (AML). " 12/01/1984 - "Selected studies of daunorubicin in adult acute nonlymphocytic leukemia." 09/24/2009 - "High-dose daunorubicin in older patients with acute myeloid leukemia." Order ALL the reference details at left...
3.	Etoposide (VP 16)FDA LinkGeneric 12/01/1992 - "In a randomized trial in previously untreated patients with ANLL, etoposide significantly prolonged remission duration. " 02/01/1997 - "Ten patients received HDAC/VP-16 as post-remission intensification therapy; five patients (four ANLL, one relapsed ALL) remain in second CR at 56, 26, 9, 5 and 2 months. " 02/01/1991 - "Etoposide is active in ANLL and prolongs remission when used as induction therapy." 01/01/1991 - "Etoposide is active in ANLL and prolongs remission when used in induction therapy." 11/01/1981 - "We conclude that the intensive treatment with VP-16-213 plus 5AZ can effectively induce remission in patients with refractory advanced acute nonlymphocytic leukemia." Order ALL the reference details at left...
4.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/01/1982 - "Finally, the present data are extrapolated to the current treatment of human acute myelocytic leukemia in complete remission with high-dose cyclophosphamide in combination with supralethal total-body irradiation." 01/01/1983 - "Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model." 12/15/1984 - "Four patients with acute myeloid leukemia (AML) were treated with high-dose cyclophosphamide and total body irradiation followed by reinfusion of a portion of their own bone marrow collected during remission. " 12/01/1986 - "Seventy-five patients with acute nonlymphoblastic leukemia (ANL) in first remission were treated with cyclophosphamide, 60 mg/kg on each of two consecutive days followed by total body irradiation (TBI) at an exposure rate of 4-6 cGy/min from two opposing 60Co sources. " 12/01/1986 - "From january 1984 to may 1986, 31 patients, 15 ANLL, 8 ALL (in remission status) and 8 NHL (6 in remission, 2 in relapse) have been treated with chemo-radiotherapy [cyclophosphamide 60 mg/kg X 2 days + total body irradiation (TBI): 10 Gy/1 fr. " Order ALL the reference details at left...
5.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/01/2003 - "Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)." 09/01/1997 - "Complete remission in three patients with acute myeloblastic leukemia by administration of G-CSF without antileukemic agents." 06/01/1995 - "G-CSF combined conditioning regimen seems to be effective for ANLL in complete remission (CR) probably by in vivo purging of residual leukemic cells. " 09/17/2009 - "In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation." 07/01/2008 - "G-CSF-induced remission in two cases of acute myeloid leukemia." Order ALL the reference details at left...
6.	Mitoxantrone (Novantrone)FDA LinkGeneric 01/01/1985 - "Of the 25 patients who received mitoxantrone 10 mg/m2 X 5, two of 10 with ANLL in relapse, one of five with ALL in relapse achieved complete remission, and one of seven with blastic phase CML responded. " 06/01/2004 - "Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML). " 10/01/1992 - "The study confirms the efficacy of the mitoxantrone-containing combination as a first-line therapy for ANLL." 06/01/1999 - "[A study of mitoxantrone with other chemical agents in treating 126 cases of adult acute myeloid leukemia]" 03/01/1987 - "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia." Order ALL the reference details at left...
7.	Interleukin-2 (IL2)IBA 12/01/1997 - "PURPOSE: Several studies have been conducted in Italy to assess the activity of recombinant interleukin-2 (rIL-2) in patients with relapsed-refractory acute myelogenous leukemia (AML) and in AML patients in second complete remission (CR) who are not eligible for standard therapy. " 10/01/2002 - "We have treated 20 patients, affected by acute myelogenous leukemia in advanced phase of the disease, with intravenous high-dose recombinant interleukin-2 (IL2) as induction treatment, achieving a complete remission (CR) in 11/20 of patients (55%). " 04/01/1999 - "The authors investigated whether IL-2 may improve the duration of complete remission (CR) and survival in acute myelogenous leukemia (AML) patients in first CR. " 04/01/1999 - "A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission." 07/01/1996 - "Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2." Order ALL the reference details at left...
8.	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/01/2004 - "This study has been carried out in our clinic in order to evaluate the efficiency of the acute nonlymphoblastic leukemia protocol which includes idarubicin. " 10/01/1999 - "A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients." 01/01/2004 - "The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia." 06/15/2002 - "A 64-year-old male was treated for acute myeloid leukemia with idarubicin and cytarabin. " 01/01/2001 - "[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases]" Order ALL the reference details at left...
9.	AntigensIBA 08/01/2008 - "These results indicate that allo-HSCT is a procedure able to rescue a significant proportion of children with acute myeloid leukemia in second complete remission, especially if an human leukocyte antigen-compatible relative is employed as donor. " 01/01/1992 - "The relationship between the level of differentiation of ANLL cells as determined by their antigen phenotype and the clinical outcome of treatment, including complete remission (CR) rate, survival, and event-free survival, was evaluated. " 01/01/1987 - "Expression of CD-15 antigen on leukemic cells--a new prognostic factor for ability to achieve complete remission and for survival in ANLL." 01/01/1986 - "CD-15 antigen detected by the VIM-D5 monoclonal antibody for prediction of ability to achieve complete remission in acute nonlymphocytic leukemia." 10/15/2004 - "Although KIR-ligand mismatch is clearly associated with improved survival in haploidentical ASCT for acute myeloid leukemia, its role in unrelated human leukocyte antigen-mismatched ASCT is more controversial. " Order ALL the reference details at left...
10.	Busulfan (Busulfex)FDA Link 02/01/2005 - "Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. " 09/01/2000 - "Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia." 01/01/1994 - "Moreover, patients with acute myelogenous leukemia or those transplanted after busulfan or total-body irradiation conditioning regimens had a slower engraftment (p < 0.08). " 12/01/1961 - "The role of Myleran in acute myelocytic leukemia." 11/01/2008 - "Busulfan (Bu) resistance is a major obstacle to hematopoietic stem cell transplantation (HSCT) of patients with chronic or acute myelogenous leukemia (CML or AML). " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 05/01/1992 - "Most results obtained by different study and analytic designs favor that matched allogeneic BMT is superior to chemotherapy in young adults with ANLL in first remission. " 10/01/2007 - "Most adult patients with acute myeloid leukemia (AML) who reach a complete remission (CR) after induction chemotherapy will relapse if they do not receive further therapy. " 03/01/1996 - "SUMMARY: Most patients with acute myelogenous leukemia achieve complete remission but are not cured with chemotherapy alone. " 06/01/2001 - "Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group." 04/01/1996 - "Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study." Order ALL the reference details at left...
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 03/01/1992 - "In the attempt to evaluate the role of Autologous and Allogeneic Bone Marrow Transplantation, we have retrospectively analyzed 159 patients with Acute Myeloid Leukemia in first complete remission treated in our Unit, most of whom were referred from other Institutions. " 02/01/1992 - "New approaches are needed to increase the cure rate substantially, and autologous bone marrow transplantation appears to be the most promising treatment modality in acute myeloid leukemia. " 01/01/1992 - "Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. " 05/01/2004 - "On the basis of observations from dog models and human studies, we hypothesized that a low-dose (550 cGy), single-exposure total body irradiation (TBI)-based regimen would result in improved survival when given to adult patients with acute myelogenous leukemia (AML) who were undergoing unrelated donor bone marrow transplantation in complete remission (CR). " 07/01/1993 - "PURPOSE: This study compares outcomes of autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in untreated first relapse (REL1) or in second complete remission (REM2). " Order ALL the reference details at left...
3.	Transplants (Transplant) 08/20/2009 - "In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source. " 10/01/2002 - "Both patients tolerated the procedure with no effect on viral load and improved CD4 counts, and patient 1 remains in complete remission from acute myelogenous leukemia 3 years post transplant. " 07/01/2002 - "A 19-year-old male with de novo acute myeloid leukemia (AML) in complete remission received a bone marrow transplant from a HLA-matched donor. " 05/01/2002 - "RESULTS: At a median follow-up of 35.5 months (range 14-119), of the 14 patients responding to first-line therapy but who relapsed > 6 months off therapy, 10 (72%) are alive, well and in complete remission (CR), 2 (14%) are alive with disease at 39 and 83 months from transplant, and 2 (14%) died 26 and 63 months after their transplant from acute myeloid leukemia and HD, respectively. " 05/01/2002 - "RESULTS: At a median follow-up of 35.5 months (range 14-119), of the 14 patients responding to first-line therapy but who relapsed > 6 months off therapy, 10 (72%) are alive, well and in complete remission (CR), 2 (14%) are alive with disease at 39 and 83 months from transplant, and 2 (14%) died 26 and 63 months after their transplant from acute myeloid leukemia and HD, respectively. " Order ALL the reference details at left...
4.	Transplantation (Transplant Recipients) 11/01/1990 - "A randomized trial of 12.0 Gy versus 15.75 Gy of total body irradiation (TBI) was performed in patients with acute myeloid leukemia undergoing allogeneic marrow transplantation while in first complete remission. " 12/15/2007 - "Here, we compared the performance of the HCT-CI to 2 other indices and then tested its capacity to predict outcomes among 2 cohorts of patients diagnosed with a single disease entity, acute myeloid leukemia in first complete remission, who underwent transplantation at either FHCRC or M. " 06/01/2000 - "Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis." 01/01/2000 - "Allogenic peripheral blood stem cells transplantation (BCT, allo-PBSCT) have an established place in currently active protocols at the University of Calgary, we now use BCT as the third approach for acute myeloid leukemia (AML) in first complete remission (CR). " 02/01/1999 - "Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. " Order ALL the reference details at left...
5.	Stem Cell Transplantation 08/01/2006 - "Most studies showing that autologous stem cell transplantation (ASCT) is feasible in older patients with acute myeloid leukemia (AML) referred to highly selected patients considered as eligible after complete remission (CR) achievement and bone marrow or peripheral blood stem cell (PBSC) collection. " 04/01/2008 - "Our period analysis reveals major improvement on the population level in long-term prognosis of younger patients with acute myeloblastic leukemia, most likely explained by multiple incremental improvements in care including better and more specific diagnosis, improvements in and extension of the use of stem cell transplantation and high dose therapy, and improved supportive care." 06/10/2009 - "Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials." 03/01/2007 - "Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study." 08/15/2003 - "Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial." Order ALL the reference details at left...